Skip to main content
OpenTrials
Completed

NCT Number: NCT00708201

A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

This study is being conducted to determine whether alvimopan can accelerate recovery of gastrointestinal function following radical cystectomy when compared with a placebo. Secondary objectives of the study are:

* to evaluate the effect of alvimopan on hospital length of stay * to evaluate the effect of alvimopan on prespecified postoperative ileus (POI)-related morbidities * to evaluate the overall and cardiovascular safety of alvimopan

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Saddleback Memorial Medical Center, Laguna Hills, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • are either Male or Female at least 18 years of age
  • are scheduled for radical cystectomy
  • are scheduled to receive postoperative pain management with intravenous participant-controlled opioid analgesics

Exclusion criteria

  • are scheduled for a partial cystectomy
  • have taken more than 3 doses of opioids (oral or parenteral) within 7 days before the day of surgery

Treatment and study plan

Alvimopan

Drug

Other names: ADL2698, Entereg

Placebo

Drug

Primary outcomes

  1. Mean Time to Achieve GI2 Analyzed by Kaplan-Meier (KM) Estimates and Cox Proportional Hazards (PH) Model

    Time frame: From day of surgery (Day 0) up to 10 days in hospital

    Time to achieve recovery of gastrointestinal (GI) function as measured by a composite endpoint of both upper GI recovery (toleration of solid food) and lower GI recovery (first bowel movement [BM]) using KM Estimates and Cox PH Model. This endpoint was referred to as GI2. GI2 was calculated as GI2 = maximum (max) (solids, BM). The KM estimate reported below is biased because of the censoring of the last observation.

    Censoring Rules for Study Participants who:

    Completed: the censored time for the event was determined as: censored time = minimum [maximum (time of/to last GI assessment, time of/to hospital discharge order written), study duration].

    Discontinued: censored time = maximum (time of/to last GI assessment, time of/to discontinuation)

Secondary outcomes

  1. Mean Time to Ready for Discharge From Hospital Analyzed by KM Estimates and Cox PH Model

    Time frame: Day of surgery (Day 0) up to 10 days in hospital

    The endpoint of "time to ready for discharge" was based solely on the recovery of GI function as determined by the surgeon. The KM estimate reported below is biased because of the censoring of the last observation.

    Censoring Rules for Study Participants who:

    Completed: the censored time for the event was determined as: censored time = minimum [maximum (time of/to last GI assessment, time of/to hospital discharge order written), study duration].

    Discontinued: censored time = maximum (time of/to last GI assessment, time of/to discontinuation)

  2. Mean Time to Discharge Order Written (DOW) Using KM Estimates

    Time frame: Day of surgery (Day 0) up to 10 days in hospital

    The KM estimate reported below is biased because of the censoring of the last observation.

    Censoring Rules for Study Participants who:

    Completed: the censored time for the event was determined as: censored time = minimum [maximum (time of/to last GI assessment, time of/to hospital discharge order written), study duration].

    Discontinued: censored time = maximum (time of/to last GI assessment, time of/to discontinuation)

  3. Postoperative Length of Stay (LOS)

    Time frame: Day of surgery (Day 0) to the day of hospital DOW

    The postoperative LOS was determined by the difference between the date of hospital DOW and the date of surgery; that is, the postoperative LOS for a participant was calculated as follows: (date of DOW) - (date of surgery).

  4. Percentage of Participants Considered Postoperative LOS Responders

    Time frame: Day of surgery (Day 0) up to 7 days after surgery

    A participant was considered a postoperative LOS responder if the postoperative LOS was less than or equal to 7 days. The postoperative LOS for a participant was calculated as follows: (date of DOW) - (date of surgery). Participants with missing data were considered nonresponders.

  5. Percentage of Participants With Postoperative Morbidity (POM)

    Time frame: During hospitalization or within 7 days after discharge

    POM was defined as the need for postoperative nasogastric (NG) tube insertion, hospital stay prolonged because of postoperative ileus (POI) (as determined by the investigator), or readmission (readmiss) to the hospital (hosp) for POI within 7 days (d) after discharge.

  6. Percentage of Participants Considered G12 Responders at 5 Cutoff Time Points

    Time frame: Day of surgery (Day 0) through PSD 3, PSD 4, PSD 5, PSD 6, and PSD 7

    Time to achieve recovery of GI function was measured by a composite endpoint of time to first BM and time to tolerate first solid food (solids). This endpoint was referred to as GI2, and GI2 was calculated as follows: GI2 = max (solids, BM). GI2 responders were defined as those participants who met all the following criteria: achieved GI2 by the cutoff point, did not have hospital stay prolonged because of POI, and did not have readmission for POI within 7 days of actual hospital discharge. Postsurgery Days (PSD) were measured in 24 hour increments after surgery.

  7. Percentage of Participants Considered DOW Responders at 5 Cutoff Time Points

    Time frame: Day of surgery (Day 0) through PSD 3, PSD 4, PSD 5, PSD 6, and PSD 7

    DOW responders were defined as those participants who met all the following criteria: achieved DOW by the cutoff point, did not have hospital stay prolonged because of POI, and did not have readmission for POI within 7 days of actual hospital discharge. PSD were measured in 24 hour increments after surgery.

  8. Percentage of Participants With Blinded Adjudicated Cardiovascular (CV) Events

    Time frame: Baseline to 30 days post discharge

    CV events of interest included congestive heart failure, CV death, cerebrovascular accident, myocardial infarction, serious arrhythmia, and unstable angina. CV events were adjudicated by a blinded external committee.

Sponsors and collaborators

Lead sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Industry

Registry information

Official study title

A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy.

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Jul 2, 2008
Registry last updated
Jan 8, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.